



SUGGESTED FORMULA

Testosterone 1mg Gelatin Troches

Version number: 1.0

Volume or quantity: 24 Troches

Testosterone, Micronized, USP (T1006)	0.24gm
*Gelatin Base	43.08
Colloidal Silicon Dioxide, NF (S1510)	0.240gm
Stevia Leaves Extract, Sweet, Powder (S1964)	0.500gm
Acacia, Spray-Dried Powder, NF (GU115)	0.400gm
Anhydrous Citric Acid, Powder, USP (CI131)	0.575gm
Flavor	XmL

SUGGESTED COMPOUNDING PROCEDURES

*See Formulation for Gelatin Base on SpectrumRx.com under formulations

**It is important to calibrate the molds you are using prior to compounding and adjust formula accordingly. This formula is based on a mold that holds approximately 1.05gm

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh/measure each ingredient.
3. Mix the Atropine Sulfate, Colloidal Silicon Dioxide, Stevia powder, Acacia powder and Citric acid powder
4. Use a water bath to heat the gelatin base until it is fluid
5. Incorporate the powders from Step#3 and mix until uniform
6. Cool slightly, add the flavor and mix well
7. Pour into the desired troche molds and allow the mixture to cool
8. Package and Label
9. Suggested Quality assessments:
 - a. color, texture, appearance
 - b. weights
 - c. mixing and filling/potency studies
 - d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned using the current USP <795> Standards

Precautions should be taken when compounding hormones. These may be absorbed through skin, mucous membranes and lungs. Wear appropriate personal protective equipment – and inform personnel of the risk. Mix and prepare in vented enclosure (hood). Pregnant women and personnel with hormone related cancers should not compound hormone preparations.

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

6/18 rd